Depressive symptomatology in young adults with a history of MDMA use: A longitudinal analysis

Journal of Psychopharmacology

Volumn 22, Issue 1, 2008, Pages 47-54

  Falck, Russel S ^a   Jichuan Wang, ^a   Carlson, Robert G ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

BDI; Depression; Depressive symptomatology; Ecstasy; Longitudinal analysis; MDMA; Substance abuse

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENZODIAZEPINE DERIVATIVE; OPIATE;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; COLLEGE; DEPRESSION; DRUG ABUSE; DRUG USE; EDUCATION; ETHNICITY; FEMALE; GENDER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; DEPRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SEX CHARACTERISTICS;

EID: 37749051899     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107078293     Document Type: Article

References (40)

1. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561 - 571
2. Beck A.T., Steer R.A. (1993) Beck Depression Inventory manual. Psychological Corporation, San Antonio, TX
3. Beck A.T., Steer R.A., Brown G.K. (1996) Beck Depression Inventory manual, 2 nd edn. The Psychological Corporation, San Antonio, TX
4. Carlson R.G., Wang J., Falck R.S., Siegal H.A. (2005) Drug use practices among MDMA/Ecstasy users in Ohio: a latent class analysis. Drug Alcohol Depend 79: 167 - 179
5. Cole J.C., Sumnall H.R. (2002) The BDI of the beholder. J Psychopharmacol 16: 103
6. Curran H.V. (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42: 34 - 41
7. Curran H.V., Travill R.A. (1997) Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). week-end 'high' followed by mid-week low. Addiction 92: 821 - 831
8. Darke S., Ross J. (1997) Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend 48: 135 - 141
9. Darke S., Ross J. (2002) Suicide among heroin users: rates, risk factors and methods. Addiction 97: 1383 - 1394
10. Daumann J., Hensen G., Thimm B., Rezk M., Till B., Gouzoulis-Mayfrank E. (2004) Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology 173: 398 - 404
11. de Win M M L, Reneman L., Reitsma J.B., den Heeten G.J., Booij J., van den Brink W. (2004) Mood disorders and serotonin transporter density in ecstasy users - the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 173: 376 - 382
12. Falck R.S., Wang J., Carlson R.G., Siegal H.A. (2006 a) Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio. Addict Behav 31: 90 - 101
13. Falck R.S., Carlson R.G., Wang J., Siegal H.A. (2006 b) Psychiatric disorders and their correlates among young adult MDMA users in Ohio. J Psychoactive Drugs 38: 19 - 29
14. Fleckenstein A.E., Gibb J.W., Hanson G.R. (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 406: 1 - 13
15. Goodwin R.D., Hasin D.S. (2002) Sedative use and misuse in the United States. Addiction 97: 555 - 562
16. Green A.R., Mechan A.O., Elliot J.M., O'Shea E., Colado M.I. (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev 55: 463 - 508
17. Guillot C., Greenway D. (2006) Recreational ecstasy use and depression. J Psychopharmacol 20: 411 - 416
18. Hanson K.L., Luciana M. (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34: 229 - 246
19. Heckathorn D.D. (1997) Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl 44: 174 - 199
20. Heckathorn D.D., Semaan S., Broadhead R.S., Hughes J.J. (2002) Extensions of respondent-driven sampling: a new approach to the study of injection drug users aged 18-25. AIDS Behav 6: 55 - 67
21. Huizink A C., Ferdinand R.F., van der Ende J., Verhulst F.C. (2006) Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 332: 825 - 828
22. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: 8 - 19
23. Lieb R., Schuetz C.G., Pfister H., von Sydow K., Wittchen H-U. (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68: 195 - 207
24. MacInnes N., Handley S.L., Harding G F A (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15: 181 - 186
25. McCardle K., Luebbers S., Carter J.D., Croft R.J., Stough C. (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 173: 434 - 439
26. Milani R.M., Parrott A.C., Turner J J D, Fox H.C. (2004) Gender differences in self-reported anxiety, depression, and somatization among ecstasy/MDMA polydrug users, alcohol/tobacco users, and nondrug users. Addict Behav 29: 965 - 971
27. Morgan M.J., McFie L., Fleetwood L.H., Robinson J.A. (2002) Ecstasy (MDMA). are the psychological problems associated with its use reversed by prolonged abstinence? Psychopharmacology 159: 294 - 303
28. Morton J. (2005) Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5: 79 - 86
29. Pichini S., Poudevida S., Pujadas M., Menoyo E., Pacifici R., Farré M., de la Torre R. (2006) Assessment of chronic exposure to MDMA in a group of consumers by segmental hair analysis. Ther Drug Monit 28: 106 - 109
30. Raudenbush S.W., Bryk A.S. (2002) Hierarchical linear models: applications and data analysis methods, 2 nd edn. Sage Publications, Thousand Oaks, CA
31. Ricaurte G.A., DeLanney L.E., Irwin I., Langston J.W. (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res Bull 446: 165 - 168
32. Robins L.N., Locke B.Z., Regier D.A. (1991) An overview of psychiatric disorders in America. In Robins L N, Regier D A (eds). Psychiatric disorders in America, pp. 328 - 386. The Free Press, New York
33. Roeloffs C.A., Wells K.B., Ziedonis D., Tang L., Unützer J. (2002) Problem substance use among depressed patients in managed primary care. Psychosomatics 43: 405 - 412
34. Roiser J.P., Sahakian B.J. (2004) Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology (Berl) 173: 411 - 417
35. SAS Institute (2004) SAS/STAT 9.1 user's guide. SAS Institute, Inc., Cary, NC Snijders T A B, Bosker R.J. (1994) Modeled variance in two-level models. Soc Meth Res 22: 342 - 363
36. Stuerenburg H.J., Petersen K., Baumer T., Rosenkranz M., Buhmann C., Thomasius R. (2002) Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuroendocrinol Lett 23: 259 - 261
37. Sumnall H.R., Cole J.C. (2005) Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. J Psychopharmacol 19: 84 - 92
38. Thomasius R., Zapletalova P., Petersen K., Buchert R., Andresen B., Wartberg L., Nebeling B., Schmoldt A. (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20: 211 - 225
39. Verkes R.J., Gijsman H J., Pieters M S M, Schoemaker R.C., de Visser S., Kuijpers M., Pennings E J M, de Bruin D., Van de Wijngaart G., Van Gerven J M A, Cohen A.F. (2001) Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl) 153: 196 - 202
40. Wang J., Carlson R.G., Falck R.S., Siegal H.A., Rahman A., Li L. (2005) Respondent-driven sampling to recruit MDMA users: a methodological assessment. Drug Alcohol Depend 78: 147 - 157